(Q34996187)

5 August 2017

1 reference

title

Vitespen: a preclinical and clinical review (English)

1 reference

5 August 2017

Christopher G Wood

1

1 reference

5 August 2017

Peter Mulders

series ordinal

2

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 August 2009

1 reference

5 August 2017

1 reference

5 August 2017

volume

5

1 reference

5 August 2017

issue

6

1 reference

5 August 2017

page(s)

763-774

1 reference

Heat-shock protein-peptide complex-96 for the treatment of cancer

5 August 2017

cites work

1 reference

Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway

21 January 2018

1 reference

Primary tumor tissue lysates are enriched in heat shock proteins and induce the maturation of human dendritic cells.

21 January 2018

1 reference

CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin

21 January 2018

1 reference

Vaccination with heat shock protein-peptide complexes: from basic science to clinical applications

21 January 2018

1 reference

Tumor rejection antigens of chemically induced sarcomas of inbred mice

21 January 2018

1 reference

Immunization with heat shock protein 70 from methylcholanthrene-induced sarcomas induces tumor protection correlating with in vitro T cell responses

21 January 2018

1 reference

Enhanced efficacy of tumor cell vaccines transfected with secretable hsp70.

21 January 2018

1 reference

Forced expression of heat-shock protein 70 increases the secretion of Hsp70 and provides protection against tumour growth

21 January 2018

1 reference

Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells.

21 January 2018

1 reference

The immunobiology of cancer immunosurveillance and immunoediting

21 January 2018

1 reference

Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study

21 January 2018

1 reference

A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma

21 January 2018

1 reference

Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma

21 January 2018

1 reference

Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group.

21 January 2018

1 reference

Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings

21 January 2018

1 reference

An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial

21 January 2018

1 reference

Prognostic significance of clinicopathologic and deoxyribonucleic acid flow cytometric variables in non-metastatic renal cell carcinoma in the modern era.

21 January 2018

1 reference

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

21 January 2018

1 reference

Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits

21 January 2018

1 reference

How tumours escape mass destruction

21 January 2018

1 reference

Cancer vaccines: clinical development challenges and proposed regulatory approaches for patient access to promising treatments.

21 January 2018

1 reference

Toward the harmonization of immune monitoring in clinical trials: quo vadis?

21 January 2018

1 reference

A clinical development paradigm for cancer vaccines and related biologics

21 January 2018

1 reference

Statistics in medicine--reporting of subgroup analyses in clinical trials.

21 January 2018

1 reference

Enhancement of Cancer Radiation Therapy by Use of Adenovirus-Mediated Secretable Glucose-Regulated Protein 94/gp96 Expression

21 January 2018

1 reference

Vaccination of Metastatic Melanoma Patients With Autologous Tumor-Derived Heat Shock Protein gp96-Peptide Complexes: Clinical and Immunologic Findings

21 January 2018

1 reference

A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-α in metastatic melanoma patients

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FON.09.46

1 reference

5 August 2017

1 reference